Regeneron Pharmaceuticals Stock News

Related Stocks: HUM , BGEPF.PFD , LBRDK , SCHW , WMG , BAC , NSRGY , JCI , REGN ,

Stocks Analysis by Zacks Investment Research covering: Eli Lilly and Company, Pfizer Inc, Regeneron Pharmaceuticals Inc. Read Zacks Investment Research''s latest article on Investing.com

Ben Emons, Medley Global Advisors, joins Closing Bell to discuss the health care sector and whether now's the time to buy.

HHM Wealth Advisors LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 625.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 145 shares of the biopharmaceutical companys stock after buying an additional 125 shares during the []

Sculati Wealth Management LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 5.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 2,067 shares of the biopharmaceutical companys stock after purchasing an additional 105 shares during the quarter. Sculati Wealth Management LLCs []

Regeneron (REGN) closed the most recent trading day at $606.81, moving +0.61% from the previous trading session.

We take a look at the data reported so far on antibody treatments by Regeneron (REGN), AstraZeneca (AZN) and Vir (VIR) amid the Omicron variant scare. The results have been mixed mostly.

Our indicative theme on Covid-19 Treatment Stocks – which includes biotech and pharma companies selling or developing treatments for the Covid-19 virus – is up by 25% year-to-date, compared to the

Trust Asset Management LLC lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,004 shares of the biopharmaceutical companys stock after buying an additional 68 shares during the quarter. Trust Asset Management LLCs holdings in []

Related Stocks: PYPL , EA , PLNT , UPS , CRM , BIIB , LYV , REGN , UNH , EOG , MA , FCX , MMM , BABA , MRK , FDX ,

Atwood & Palmer Inc. boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,302 shares of the biopharmaceutical companys stock after acquiring an additional 126 shares during the period. Regeneron Pharmaceuticals []

Kovitz Investment Group Partners LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 8.0% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,631 shares of the biopharmaceutical companys stock after selling 314 shares during the quarter. Kovitz Investment Group Partners []

HC Wainwright reiterated their buy rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a report released on Monday morning, AnalystRatings.com reports. REGN has been the subject of a number of other research reports. The Goldman Sachs Group initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Monday, December 6th. They issued a []

When the operating income margin continues to grow, it means a company is becoming more efficient in generating profits from its operating activities.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) lost 2.0% in the stock market this morning after the biotech company said its COVID-19 antibody cocktail loses potency against the latest Omicron variant o